Construction is underway for a new cell therapy manufacturing facility in Devens, MA, a part of Bristol Myers Squibb’s significant investment to support clinical and commercial manufacturing of transformative cell therapies for patients with aggressive hematological cancers.   The Devens site is the latest investment from Bristol Myers Squibb as the company expands its global manufacturing network. The 244,000 square foot facility adds to the company’s already established state-of-the-art cell t...